CNBC
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
EconomyDaily Composite
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
C
Source
CNBC
Read full article at CNBC
Opens original article in a new tab
Advertisement

